Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Age-adjusted Charlson comorbidity index
Prognostic factor
Recurrent glioblastoma
Surgery
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
21 Jan 2022
21 Jan 2022
Historique:
received:
02
11
2020
accepted:
22
12
2021
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
For recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive surgery, re-irradiation or chemotherapy. Age and the Karnofsky Performance Status Scale (KPSS) are used to make decisions for these patients as these are established as prognostic factors in the initial diagnosis of GB. This study's aim was to evaluate preoperative patient comorbidities by using the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for recurrent GB patients. In this retrospective analysis we could include 123 patients with surgery for primary recurrence of GB from January 2007 until December 2016 (43 females, 80 males, mean age 57 years (range 21-80 years)). Preoperative age, sex, ACCI, KPSS and adjuvant treatment regimes were recorded for each patient. Extent of resection (EOR) was recorded as a complete/incomplete resection of the contrast-enhancing tumor part. Median overall survival (OS) was 9.0 months (95% CI 7.1-10.9 months) after first re-resection. Preoperative KPSS > 80% (P < 0.001) and EOR (P = 0.013) were associated with significantly improved survival in univariate analysis. Including these factors in multivariate analysis, preoperative KPSS < 80 (HR 2.002 [95% CI: 1.246-3.216], P = 0.004) and EOR are the only significant prognostic factor (HR 1.611 [95% CI: 1.036-2.505], P = 0.034). ACCI was not shown as a prognostic factor in univariate and multivariate analyses. For patients with surgery for recurrent glioblastoma, the ACCI does not add further information about patient's prognosis besides the well-established KPSS and extent of resection.
Sections du résumé
BACKGROUND
BACKGROUND
For recurrent glioblastoma (GB) patients, several therapy options have been established over the last years such as more aggressive surgery, re-irradiation or chemotherapy. Age and the Karnofsky Performance Status Scale (KPSS) are used to make decisions for these patients as these are established as prognostic factors in the initial diagnosis of GB. This study's aim was to evaluate preoperative patient comorbidities by using the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for recurrent GB patients.
METHODS
METHODS
In this retrospective analysis we could include 123 patients with surgery for primary recurrence of GB from January 2007 until December 2016 (43 females, 80 males, mean age 57 years (range 21-80 years)). Preoperative age, sex, ACCI, KPSS and adjuvant treatment regimes were recorded for each patient. Extent of resection (EOR) was recorded as a complete/incomplete resection of the contrast-enhancing tumor part.
RESULTS
RESULTS
Median overall survival (OS) was 9.0 months (95% CI 7.1-10.9 months) after first re-resection. Preoperative KPSS > 80% (P < 0.001) and EOR (P = 0.013) were associated with significantly improved survival in univariate analysis. Including these factors in multivariate analysis, preoperative KPSS < 80 (HR 2.002 [95% CI: 1.246-3.216], P = 0.004) and EOR are the only significant prognostic factor (HR 1.611 [95% CI: 1.036-2.505], P = 0.034). ACCI was not shown as a prognostic factor in univariate and multivariate analyses.
CONCLUSION
CONCLUSIONS
For patients with surgery for recurrent glioblastoma, the ACCI does not add further information about patient's prognosis besides the well-established KPSS and extent of resection.
Identifiants
pubmed: 35062885
doi: 10.1186/s12883-021-02532-x
pii: 10.1186/s12883-021-02532-x
pmc: PMC8780246
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Informations de copyright
© 2022. The Author(s).
Références
J Neurooncol. 2017 May;132(3):419-426
pubmed: 28374095
J Neurooncol. 2015 May;122(3):567-73
pubmed: 25700836
J Neurooncol. 2013 Jul;113(3):485-93
pubmed: 23666202
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Ann Hematol. 2017 Jan;96(1):9-16
pubmed: 27752822
Head Neck. 2003 Jul;25(7):535-42
pubmed: 12808656
Am J Clin Oncol. 2019 May;42(5):481-486
pubmed: 30973372
J Neurooncol. 2018 Sep;139(3):599-608
pubmed: 29846896
Radiother Oncol. 2014 Jan;110(1):91-7
pubmed: 24412015
Cancer Res. 1947 Jan;7(1):50
pubmed: 20278229
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Neurology. 2015 Feb 17;84(7):710-9
pubmed: 25609769
J Neurosurg. 2012 Dec;117(6):1032-8
pubmed: 23039151
J Neurooncol. 2017 Feb;131(3):585-591
pubmed: 27844310
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):211-7
pubmed: 20732762
J Neurosurg. 2014 Oct;121(4):802-9
pubmed: 25061868
Radiother Oncol. 2010 Dec;97(3):377-81
pubmed: 20855119
JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1059-65
pubmed: 26447790
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:5168-5171
pubmed: 28269429
Neurosurgery. 2014 Nov;75(5):491-9; discussion 498-9
pubmed: 24991712
Neurosurgery. 2016 Nov;79(5):678-689
pubmed: 27409404
Curr Neurol Neurosci Rep. 2017 Apr;17(4):35
pubmed: 28324304
J Neurooncol. 2017 Jan;131(2):377-384
pubmed: 27826681
J Clin Oncol. 2009 Apr 20;27(12):1983-91
pubmed: 19289616
J Clin Oncol. 2010 Aug 20;28(24):3838-43
pubmed: 20644085
Urol Int. 2014;93(3):303-10
pubmed: 25139069
Oncotarget. 2017 Mar 17;8(33):55600-55612
pubmed: 28903447
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Neurosurg. 2003 Jun;98(6):1175-81
pubmed: 12816260
Neuro Oncol. 2016 Jan;18(1):96-104
pubmed: 26243790
JAMA Oncol. 2018 Sep 1;4(9):1254-1262
pubmed: 29931168
Neurol Clin. 2018 Aug;36(3):395-419
pubmed: 30072062
Curr Opin Neurol. 2014 Dec;27(6):666-74
pubmed: 25364955
PLoS One. 2015 Jan 24;10(1):e0117323
pubmed: 25617629
Clin Cancer Res. 2009 Nov 1;15(21):6683-93
pubmed: 19861461
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neurosurgery. 1987 Nov;21(5):615-21
pubmed: 2827052
J Clin Pathol. 2020 Feb;73(2):112-115
pubmed: 31422371
Clin Neurol Neurosurg. 2016 Mar;142:60-64
pubmed: 26811867
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3
pubmed: 9574634
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Eur J Clin Invest. 2021 Feb;51(2):e13373
pubmed: 32780431
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931